CWBR · CohBar Inc

-

Please sign in to comment on CWBR

1 Comment

Admin

4 years, 10 months ago

CohBar, Inc is currently in a long term downtrend where the price is trading 5.8% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

CohBar, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 337.6% to $-16M since the same quarter in the previous year.

Finally, its free cash flow fell by 8.6% to $-2M since the same quarter in the previous year.

Based on the above factors, CohBar, Inc gets an overall score of 1/5.

Exchange	OTCMKTS
CurrencyCode	USD
ISIN	US19249J1097
Sector	Healthcare
Industry	Biotechnology

Market Cap	1M
PE Ratio	None
Target Price	18
Beta	1.38
Dividend Yield	None

ABOUT

CohBar Inc

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

CWBR · CohBar Inc

-

CohBar Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest CohBar Inc using a moving average strategy